Altis Biosystems Appoints Jimmy Smedley, Ph.D. Chief Operating Officer
January 27, 2022
Altis Biosystems, Inc., developer of RepliGut®, a technology platform that produces a layer of human intestinal stem or differentiated cells of either the small intestine or colon, announced the appointment of Jimmy Smedley, Ph.D. to the role of Chief Operating Officer. Dr. Smedley brings over 20 years of scientific experience to Altis and will focus on operations and lead the company’s strategies for go-to-market, product, and services.
“Jimmy is a seasoned, trusted leader who has consistently delivered impactful results, in prior positions.” said Michael Biron, CEO of Altis. “He is highly qualified to drive strategic prioritization, with a focus on operational excellence and I have confidence in Jimmy’s ability to align Altis’ innovation with industry leading operational practices.”
Prior to joining Altis, Jimmy served in various roles at KBI Biopharma. In his tenure at KBI, he built and grew the company’s Analytical Development department from 8 to over 65 employees. Additionally, he helped develop and lead a limited cell-based assay function into a full-service, 10-person GMP laboratory, including supporting over 25 cell lines and biological potency test methods. He received a Ph.D. in Molecular Virology & Microbiology at the University of Pittsburgh School of Medicine, and a M.S., Biology from Duquesne University.